202 related articles for article (PubMed ID: 31531796)
1. ASO Author Reflections: What Role Do Surgeons Play in the Era of Effective Systemic Therapy for Melanoma?
Nelson DW; Faries MB
Ann Surg Oncol; 2019 Dec; 26(13):4619-4620. PubMed ID: 31531796
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: Survival for Stage III Melanoma-Where Do We Stand in the Current Landscape of Melanoma Therapies?
Song Y; Karakousis GC
Ann Surg Oncol; 2019 Dec; 26(13):4631-4632. PubMed ID: 31576473
[No Abstract] [Full Text] [Related]
3. ASO Author Reflections: Frequent Relapses Prior to the Start of Adjuvant Therapy in Stage IIIB/C Melanoma.
Bloemendal M; van Willigen WW; Bol KF; de Wilt JHW
Ann Surg Oncol; 2019 Nov; 26(12):3953-3954. PubMed ID: 31396780
[No Abstract] [Full Text] [Related]
4. Indications and options for systemic therapy in melanoma.
Sondak VK; Gibney GT
Surg Clin North Am; 2014 Oct; 94(5):1049-58, viii. PubMed ID: 25245967
[TBL] [Abstract][Full Text] [Related]
5. Melanoma.
Benson C; Gore ME
Cancer Chemother Biol Response Modif; 2001; 19():629-38. PubMed ID: 11686036
[No Abstract] [Full Text] [Related]
6. Update on the systemic treatment of malignant melanoma.
Lawson DH
Semin Oncol; 2004 Apr; 31(2 Suppl 4):33-7. PubMed ID: 15124132
[TBL] [Abstract][Full Text] [Related]
7. ASO Author Reflections: Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Mahuron KM; Levine LS; Daud AI
Ann Surg Oncol; 2020 Oct; 27(11):4131-4132. PubMed ID: 32488511
[No Abstract] [Full Text] [Related]
8. ASO Author Reflections: Important Factors for Adjuvant Immunotherapy Treatment Decisions for Stage II-IV Melanoma Patients and Their Clinicians.
Livingstone A; Morton RL
Ann Surg Oncol; 2020 Feb; 27(2):585-586. PubMed ID: 31673944
[No Abstract] [Full Text] [Related]
9. Advances in therapy for melanoma brain metastases.
Flanigan JC; Jilaveanu LB; Chiang VL; Kluger HM
Clin Dermatol; 2013; 31(3):264-81. PubMed ID: 23608446
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Therapy in Melanoma.
Callahan MK
Cancer J; 2016; 22(2):73-80. PubMed ID: 27111901
[TBL] [Abstract][Full Text] [Related]
11. [High-dose interferon-alpha and adjuvant treatment of melanoma with poor prognosis: requiem for a drug marketing license?].
Saiag P
Ann Dermatol Venereol; 1999 Mar; 126(3):211-3. PubMed ID: 10394432
[No Abstract] [Full Text] [Related]
12. Current and future directions in the treatment of metastatic malignant melanoma.
Baron JM; Heise R; Merk HF; Abuzahra F
Curr Med Chem Anticancer Agents; 2003 Nov; 3(6):393-8. PubMed ID: 14529447
[TBL] [Abstract][Full Text] [Related]
13. NCCN Guidelines Insights: Melanoma, Version 3.2016.
Coit DG; Thompson JA; Algazi A; Andtbacka R; Bichakjian CK; Carson WE; Daniels GA; DiMaio D; Fields RC; Fleming MD; Gastman B; Gonzalez R; Guild V; Johnson D; Joseph RW; Lange JR; Martini MC; Materin MA; Olszanski AJ; Ott P; Gupta AP; Ross MI; Salama AK; Skitzki J; Swetter SM; Tanabe KK; Torres-Roca JF; Trisal V; Urist MM; McMillian N; Engh A
J Natl Compr Canc Netw; 2016 Aug; 14(8):945-58. PubMed ID: 27496110
[TBL] [Abstract][Full Text] [Related]
14. Phase III adjuvant studies in operable malignant melanoma (review).
Lejeune FJ
Anticancer Res; 1987; 7(4B):701-5. PubMed ID: 3314671
[TBL] [Abstract][Full Text] [Related]
15. Melanoma.
Rümke P
Cancer Chemother Biol Response Modif; 1988; 10():333-43. PubMed ID: 3079389
[No Abstract] [Full Text] [Related]
16. Interferon adjuvant therapy of melanoma.
Kirkwood JM; Wazer D; Rosenstein M
Cancer; 1997 May; 79(9):1843-6. PubMed ID: 9129006
[No Abstract] [Full Text] [Related]
17. Adjuvant interferon for stage II melanoma.
Haluska FG
J Clin Oncol; 1998 Sep; 16(9):3205-6. PubMed ID: 9738597
[No Abstract] [Full Text] [Related]
18. Malignant melanoma. Why early diagnosis and treatment are crucial.
Costanzi JJ
Postgrad Med; 1988 Nov; 84(6):159-60, 163-8. PubMed ID: 3054844
[No Abstract] [Full Text] [Related]
19. Metastasectomy for Stage IV Melanoma in the Era of Effective Systemic Agents.
Ollila DW; Lopez NE; Hsueh EC
Crit Rev Oncog; 2016; 21(1-2):37-55. PubMed ID: 27481001
[TBL] [Abstract][Full Text] [Related]
20. ASO Author Reflections: Patient-Reported Outcomes of Mucinous Appendiceal Cancer Improve with Oxaliplatin HIPEC.
Moaven O; Perry KC; Votanopoulos KI; Shen P; Levine EA
Ann Surg Oncol; 2020 Mar; 27(3):781-782. PubMed ID: 31720929
[No Abstract] [Full Text] [Related]
[Next] [New Search]
